Cutaneous Melanoma Clinical Trials

23 recruiting

Cutaneous Melanoma Trials at a Glance

45 actively recruiting trials for cutaneous melanoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 21 trials, with the heaviest enrollment activity in Houston, Los Angeles, and New York. Lead sponsors running cutaneous melanoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and Melanoma Institute Australia.

Browse cutaneous melanoma trials by phase

Treatments under study

About Cutaneous Melanoma Clinical Trials

Looking for clinical trials for Cutaneous Melanoma? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cutaneous Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cutaneous Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Not Applicable

The Multicentre Selective Lymphadenectomy Trial - 3

Cutaneous Melanoma, Stage III
Melanoma Institute Australia1,500 enrolled7 locationsNCT07049276
Recruiting
Phase 1

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Esophageal CancerCutaneous MelanomaNon-Small-Cell Lung
Pfizer250 enrolled6 locationsNCT07519655
Recruiting
Phase 2Phase 3

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Unresectable MelanomaCutaneous MelanomaMelanoma (Skin Cancer)+1 more
Linnaeus Therapeutics, Inc.135 enrolled9 locationsNCT06624644
Recruiting
Phase 2

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center35 enrolled1 locationNCT05026983
Recruiting
Phase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8+35 more
M.D. Anderson Cancer Center54 enrolled1 locationNCT05039801
Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting
Phase 1Phase 2

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Advanced Solid TumorMetastatic CancerCutaneous Melanoma
Aulos Bioscience, Inc.159 enrolled18 locationsNCT05267626
Recruiting
Not Applicable

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center60 enrolled1 locationNCT06391099
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+41 more
M.D. Anderson Cancer Center800 enrolled1 locationNCT03819296
Recruiting
Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center25 enrolled1 locationNCT05098210
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Not Applicable

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8
OHSU Knight Cancer Institute1,000 enrolled1 locationNCT06673095
Recruiting
Phase 1

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaClinical Stage I Cutaneous Melanoma AJCC v8+6 more
Carlo Contreras36 enrolled1 locationNCT04697576
Recruiting
Phase 2

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Skin Squamous Cell CarcinomaMerkel Cell CarcinomaCutaneous Melanoma
Ohio State University Comprehensive Cancer Center100 enrolled1 locationNCT06223659
Recruiting

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

CholangiocarcinomaHepatocellular CarcinomaRenal Cell Carcinoma+5 more
Mohamed Abdel-Rahman500 enrolled1 locationNCT04792463
Recruiting
Not Applicable

PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma

Clinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage II Cutaneous Melanoma AJCC v8Clinical Stage 0 Cutaneous Melanoma AJCC v8
University of California, Davis36 enrolled1 locationNCT07258446
Recruiting
Phase 1

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Advanced Solid TumorCutaneous MelanomaUveal Melanoma, Metastatic
MonTa Biosciences ApS106 enrolled5 locationsNCT04855435